Search clinical trials for: Rivoroxaban

Total 474 results

Pfizer

Active, not recruiting

A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France (SIFNOS)

Atrial Fibrillation

France
Bayer
Janssen Research & Development, LLC

Completed

Clinical Outcomes Among Non-valvular Atrial Fibrillation Patients With Renal Dysfunction (CALLIPER)

Atrial Fibrillation

United States
Bayer
Janssen Research & Development, LLC

Completed

Relative Bioavailability Study in Healthy Subjects Comparing 2 Dry Powder Oral Suspensions of Rivaroxaban Under Fasting and 20 mg of an Oral Suspension of Rivaroxaban Under Fed Conditions to 10 mg of an Immediate Release Tablet Under Fasting Conditions

Pharmacokinetics

Germany
Bayer

Completed

ODiXahip - a Phase IIa Dose Escalating Proof of Principle Trial (ODiXaHip)

Thromboembolism | Prevention

Belgium, Denmark, Austria, Germany, Netherlands, Poland, Sweden, Israel, France, Norway, United Kingdom
Bayer

Completed

Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). A Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement. (RECORD 3)

Venous Thromboembolism | Prevention

Belgium, Italy, Poland, Spain, China, France, Denmark, Netherlands, Austria, Germany, Mexico, South Africa, Sweden, Colombia, Israel, Canada, Norway, Peru, Czech Republic
Fundació Institut de Recerca de l'Hospital de la...
Daiichi Sankyo

Recruiting

Real-life Clinical Outcomes of Direct Oral Anticoagulants (MACACOD) (MACACOD)

Atrial Fibrillation | Recurrent Venous Thromboembolism

Spain
University of Florida
Janssen Scientific Affairs, LLC

Completed

Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet Therapies

Coronary Artery Disease | Peripheral Arterial Disease | Atrial Fibrillation

United States
Bayer
Janssen Research & Development, LLC

Completed

Study to Gather Information How Often Venous Thromboembolism Occurs in Prostate Cancer Patients in Sweden and How This Condition is Treated With Blood Thinners (PRACTISE)

Venous Thromboembolism (VTE)

Sweden
Shenyang Northern Hospital

Not yet recruiting

Rivaroxaban or Aspirin in Patients With CHD & GD Undergoing PCI

Rivaroxaban
First Affiliated Hospital Xi'an Jiaotong University

Completed

Anticoagulation Therapy After Splenectomy in Cirrhosis Patient (ATASICP)

Liver Cirrhosis | Thrombosis | Portal Hypertension | Anticoagulant-induced Bleeding

China
Bayer
Janssen Research & Development, LLC

Completed

Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Rivaroxaban vs. Vitamin k Antagonists

Atrial Fibrillation

Germany
Bayer
Janssen Research & Development, LLC

Completed

BAY 59-7939 (Xarelto, SPAF), Non Interventional Studies

Atrial Fibrillation

Germany
National Cancer Institute (NCI)

Completed

Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma

Glioma | Glioblastoma Multiforme | Giant Cell Glioblastoma | Oligodendrogliomas | Astrocytoma, Grades II, III and IV

United States
Janssen Research & Development, LLC
Bayer

Completed

A Study of Erythromycin and Rivaroxaban in Study Participants With Normal and Reduced Kidney Function

Healthy | Renal Insufficiency

United States
Asan Medical Center
Bayer

Recruiting

Effects of aSPIrin Versus Aspirin Plus Low-dose RIvaroxaban on Carotid aTherosclerotic Plaque Inflammation (SPIRIT)

Coronary Artery Disease | Peripheral Arterial Disease | Carotid Stenosis | Atherosclerosis of Artery

Korea, Republic of
University College, London

Recruiting

OPTIMAS: OPtimal TIMing of Anticoagulation After Acute Ischaemic Stroke : a Randomised Controlled Trial (OPTIMAS)

Atrial Fibrillation | Stroke, Acute

United Kingdom
University of California, San Francisco
Patient-Centered Outcomes Research Institute; Kaiser Permanente

Completed

Anticoagulation Length of ThErapy and Risk of New Adverse evenTs In Venous thromboEmbolism Study (ALTERNATIVE)

Venous Thromboembolism | Anticoagulants and Bleeding Disorders

United States
Radboud University Medical Center

Active, not recruiting

Trained Immunity by Dual-pathway Inhibition in Coronary Artery Disease (DUALCAD)

Coronary Artery Disease

Netherlands
Duke University
Patient-Centered Outcomes Research Institute

Terminated

Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism (COVET)

Venous Thromboembolism

United States
Xijing Hospital

Recruiting

Low-dose NOAC Versus GDMT After LAAO (RECORD-III)

Atrial Fibrillation

China
Regeneron Pharmaceuticals

Completed

Assess Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban in Healthy Adult Participants

Healthy Volunteer

United Kingdom
Beijing Suncadia Pharmaceuticals Co., Ltd

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of SHR-2004 Injection in Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery

Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery
Radboud University Medical Center
Amgen

Completed

Rivaroxaban Sotorasib Interaction Study (ROSIE)

Drug Drug Interaction Study

Netherlands
National Taiwan University Hospital

Recruiting

Evaluataion of NOAC Levels in Acute Stroke

Ischemic Stroke | Anticoagulant Adverse Reaction

Taiwan
University of Birmingham
University of Oxford; University Hospital Birmingham NHS Foundation Trust; London... and other collaborators

Recruiting

Preventing Stroke, Premature Death and Cognitive Decline in a Broader Community of Patients With Atrial Fibrillation (DaRe2THINK)

Atrial Fibrillation

United Kingdom
RWTH Aachen University
Bayer

Completed

Rivaroxaban Compared to Vitamin K Antagonist Upon Development of Cardiovascular Calcification

Atrial Fibrillation or Pulmonary Embolism | Need of Long Term Oral Anticoagulation Therapy (OAT) | Existent Coronary or Valvular Calcification, or Both and Agatston Score > 50 in at Least One Location

Germany
Bayer

Completed

Accessibility to New Drugs Versus SOC in Sweden

Anticoagulation

Sweden
Pharmtechnology LLC
ClinPharmInvest, LLC

Not yet recruiting

Bioequivalence Study of Two Formulations of Rivaroxaban Tablets 20 mg in Healthy Male Volunteers Under Fed Conditions

Bioequivalence

Russian Federation
Rajaie Cardiovascular Medical and Research Center
Tehran Heart Center

Completed

Rivaroxaban vErsus Warfarin for Antithrombotic TheRapy in Patients With LeFt Ventricular Thrombus After Acute STEMI (REWARF-STEMI)

ST Segment Elevation Myocardial Infarction | Left Ventricular Thrombus

Iran, Islamic Republic of
Radboud University Medical Center

Completed

DUAL Pathway Inhibition to Improve Endothelial Function in Peripheral Artery Disease (DUAL-PAD)

Peripheral Artery Disease

Netherlands
Bayer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study

Venous Thrombosis

United Kingdom, Belgium, France, Israel, Italy, Spain, China, Hong Kong, Korea, Republic of, United States, New Zealand, Poland, India, Hungary, Singapore, Canada, Australia, Netherlands, Austria, Switzerland, Brazil, Denmark, Germany, Norw... and more
Herlev and Gentofte Hospital
Danish Society of Cardiology

Recruiting

The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE) (DANNOAC-VTE)

Deep Vein Thrombosis | Pulmonary Embolism

Denmark
Bayer
Janssen Research & Development, LLC; Population Health Research Institute

Terminated

Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS) (NAVIGATE ESUS)

Stroke

Denmark, France, Spain, China, United States, Switzerland, Germany, Greece, Korea, Republic of, Portugal, Japan, Israel, Canada, Australia, Turkey, Russian Federation, Sweden, Austria, Czechia, Poland, United Kingdom, Belgium, Brazil, Hungar... and more
Canadian Network for Observational Drug Effect...
Canadian Institutes of Health Research (CIHR); Drug Safety and Effectiveness...

Completed

Direct Oral Anticoagulants in Patients With Atrial Fibrillation (DOACs vs DOACs)

Myocardial Infarction | Ischemic Stroke | Atrial Fibrillation | All-cause Mortality | Systemic Embolization | Major Bleed

Canada
Bayer
Janssen Research & Development, LLC

Terminated

A Nationwide Observational Study Looking at Effectiveness and Bleeding Complications of NOACs vs. VKA in Non-valvular Atrial Fibrillation Patients. (PROTECT-AF)

Non-valvular Atrial Fibrillation

Norway
Ahmed AbdelMoneim Hassan Ali
Beni-Suef University

Unknown

Thromboprophylaxis in Patients Undergoing Orthopedic Surgeries; Comparison Between Rivaroxaban and Enoxaparin

Surgery--Complications | Thromboses, Deep Vein
Bayer

Completed

Anticoagulation Preference by AF Patients Study (PRiSMA-AF)

Atrial Fibrillation

Switzerland
Gines Escolar
Ministry of Health, Spain

Unknown

Reversal of the Antithrombotic Action of New Oral Anticoagulants (REVANT)

Hemorrhage | Thrombosis | Anticoagulant-induced Bleeding | Anticoagulant Overdosage

Spain
Northwestern University
National Heart, Lung, and Blood Institute (NHLBI); Medtronic

Completed

Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring (REACT COM)

Atrial Fibrillation

United States, Canada
Ohio State University

Terminated

Statin Use in Patients With Acute VTE

Venous Thromboembolism

United States
Florida Orthopaedic Institute
Orthopaedic Trauma Association

Unknown

Deep Vein Thrombosis Prophylaxis Adherence: Enoxaparin vs Rivaroxaban

Deep Vein Thrombosis | Venous Thromboembolism

United States
Assistance Publique - Hôpitaux de Paris
Bayer

Completed

Cancer Associated Thrombosis, a Pilot Treatment Study Using Rivaroxaban (CASTA-DIVA)

Venous Thromboembolism | Neoplasm

France
Fundació Institut de Recerca de l'Hospital de la...

Completed

Intracerebral Hemorrhage Due to Oral Anticoagulants: Prediction of the Risk by Magnetic Resonance (HERO)

Ischemic Stroke

Spain, Italy
Portola Pharmaceuticals

Completed

A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa

Bleeding

United States
Nanfang Hospital, Southern Medical University

Recruiting

Efficacy and Safety of Rivaroxaban in the Prevention of Venous Thromboembolism in Glioma Patients

Glioma, Malignant

China
Armed Forces Post Graduate Medical Institute (AFPGMI)...

Recruiting

Effectiveness of Combined Anticoagulation and Antithrombotic Therapy vs Antithrombotic Therapy Alone After Lower Extremity Revascularization for Peripheral Arterial Disease

PAD - Peripheral Arterial Disease | Combined Anticoagulation and Antithrombotic Therapy

Pakistan
University Hospital Inselspital, Berne
Centre Hospitalier Universitaire Vaudois

Recruiting

Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients With Liver Cirrhosis

Liver Cirrhosis

Switzerland
Assistance Publique - Hôpitaux de Paris

Active, not recruiting

Direct Oral Anticoagulants for Prevention of lEft ventRIcular Thrombus After Anterior Acute Myocardial InFarction - APERITIF (APERITIF)

Myocardial Infarction, Acute | Left Ventricular Thrombus

France
Pharmtechnology LLC
ClinPharmInvest, LLC

Unknown

Bioequivalence Study of Two Formulations of Rivaroxaban Tablets 10 mg in Healthy Male Volunteers in Fasting Conditions

Bioequivalence

Russian Federation
Canadian Network for Observational Drug Effect...
Canadian Institutes of Health Research (CIHR); Drug Safety and Effectiveness...

Completed

Direct Oral Anticoagulants and Venous Thromboembolism

Venous Thromboembolism | Major Bleed

Canada

Search clinical trials for: Rivoroxaban

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mexico

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations